21 results on '"Dasenbrook E"'
Search Results
2. 544 Food insecurity screening and local food access: contributions to nutritional outcomes at U.S. cystic fibrosis programs
- Author
-
Bailey, J., primary, Baker, E., additional, Schechter, M., additional, Robinson, K., additional, Powers, K., additional, Dasenbrook, E., additional, Hossain, M., additional, Brown, G., additional, Clemm, C., additional, and Oates, G., additional
- Published
- 2023
- Full Text
- View/download PDF
3. 28 A multi-center study of peripherally inserted central venous catheters: Predictors of difficult line insertion, malfunction, and soft tissue injury
- Author
-
Zuckerman, J., primary, Hinton, A., additional, Mermis, J., additional, Flume, P., additional, Jia, S., additional, Dasenbrook, E., additional, Dezube, R., additional, West, N., additional, Sadeghi, H., additional, Nasr, S., additional, DiMango, E., additional, Polineni, D., additional, Zemanick, E., additional, Lahiri, T., additional, Teneback, C., additional, and Gifford, A., additional
- Published
- 2022
- Full Text
- View/download PDF
4. 337: Food insecurity in the cystic fibrosis care center network during COVID-19: Prevalence, screening, and interventions
- Author
-
Bailey, J., primary, Brown, G., additional, Corbera-Hincapie, M., additional, Clemm, C., additional, Dasenbrook, E., additional, Durham, D., additional, Oates, G., additional, Reno, K., additional, Sapp, S., additional, Schechter, M., additional, and Robinson, K., additional
- Published
- 2021
- Full Text
- View/download PDF
5. SAFETY AND PHARMACOKINETICS OF INHALED VANCOMYCIN IN INDIVIDUALS WITH CYSTIC FIBROSIS: 273★
- Author
-
Jennings, M., Bucur, C., Boyle, M. P., Konstan, M., and Dasenbrook, E. C.
- Published
- 2012
6. EVALUATION OF OXYGEN-ENHANCED MRI FOR DETECTION OF EARLY-STAGE CYSTIC FIBROSIS LUNG DISEASE: 247
- Author
-
Dasenbrook, E. C., Lu, L., Flask, C. A., and Konstan, M.
- Published
- 2012
7. THE EFFECT OF THE LUNG ALLOCATION SCORE ON EARLY OUTCOMES IN LUNG TRANSPLANTATION AMONG INDIVIDUALS WITH CYSTIC FIBROSIS: 540⋆
- Author
-
Merlo, C. A., Dasenbrook, E. C., Lechtzin, N., Boyle, M. P., Orens, J. B., and Shah, A.
- Published
- 2008
8. Including Cystic-Fibrosis-Specific Variables Improves Accuracy of the Lung Allocation Score
- Author
-
Lehr, C.J., primary, Skeans, M., additional, Dasenbrook, E., additional, Faro, A., additional, Fink, A., additional, Fernandez, G., additional, and Valapour, M., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Higher PEEP in Patients With Acute Lung Injury: A Systematic Review and Meta-Analysis
- Author
-
Dasenbrook, E. C., primary, Needham, D. M., additional, Brower, R. G., additional, and Fan, E., additional
- Published
- 2011
- Full Text
- View/download PDF
10. Cystic fibrosis and survival in patients with advanced lung disease
- Author
-
Dasenbrook, E. C., primary
- Published
- 2011
- Full Text
- View/download PDF
11. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.
- Author
-
Endimiani, A., Blackford, M., and Dasenbrook, E. C.
- Published
- 2011
12. Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor.
- Author
-
Sanders DB, Mayer-Hamblett N, Rosenfeld M, Polinieni D, Dasenbrook E, Szczesniak R, and Cromwell EA
- Abstract
Background: We characterized people with cystic fibrosis (CF) ineligible by genotype (not age) for currently approved CFTR modulator therapy using data from the US CF Foundation Patient Registry (CFFPR)., Methods: We summarized clinical characteristics using CFFPR data from 2017 to 2022. Annual rate of change in percent predicted of forced expiratory volume in one second (ppFEV
1 ) was estimated using generalized estimating equations., Results: A total of 2,790 individuals with CF met inclusion criteria. In 2022, 12 % were less than 6 years old, 16 % were age 6-12 years, 18 % age 12-18 years and 54 % were ≥18 years. The proportion identified as White was 74 %, 17 % Black, and 26 % as Hispanic. The median (IQR) age at diagnosis was 1.2 (0.5, 9.1) months for children and 3.1 (0.3, 17.4) years for adults. Median (IQR) ppFEV1 among children was 91.9 (80.3; 102.4) and among adults, 74.3 (52.4; 90.4). Pancreatic enzymes were prescribed for 77.8 %. Population-level average (95 % CI) rates of decline in ppFEV1 among the pancreatic insufficient population was -1.5 per year (-1.8; -1.2) for ages 6 to <11 years, -2.2 per year (-2.6; -1.8) for ages 12 to <18 years, and -1.5 per year (-1.7; -1.3) for adults., Conclusions: We describe the CFTR modulator ineligible population in the US in 2017-2022. With a growing pipeline of therapies aimed at improving CFTR function for those who cannot benefit from modulators due to ineligibility, characterization of both the size and outcomes of these populations are critical to inform optimal clinical development plans and future clinical trials., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Elizabeth Cromwell reports financial support was provided by Cystic Fibrosis Foundation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
13. Food insecurity screening and local food access: Contributions to nutritional outcomes among children and adults with cystic fibrosis in the United States.
- Author
-
Bailey J, Baker E, Schechter MS, Robinson KJ, Powers KE, Dasenbrook E, Hossain M, Durham D, Brown G, Clemm C, Reno K, and Oates GR
- Subjects
- Humans, United States epidemiology, Male, Female, Cross-Sectional Studies, Adult, Child, Adolescent, Food Supply statistics & numerical data, Mass Screening methods, Body Mass Index, Child, Preschool, Registries, Food Insecurity, Cystic Fibrosis epidemiology, Cystic Fibrosis physiopathology, Cystic Fibrosis diagnosis, Nutritional Status
- Abstract
Background: As the nutritional status of people with CF (PwCF) is associated with their socioeconomic status, it is important to understand factors related to food security and food access that play a role in the nutritional outcomes of this population. We assessed the contributions of CF program-level food insecurity screening practices and area-level food access for nutritional outcomes among PwCF., Methods: We conducted a cross-sectional analysis of 2019 data from the U.S. CF Patient Registry (CFFPR), linked to survey data on CF program-level food insecurity screening and 2019 patient zip code-level food access. Pediatric and adult populations were analyzed separately. Nutritional outcomes were assessed with annualized BMI percentiles (CDC charts) for children and BMI (kg/m
2 ) for adults, with underweight status defined as BMIp <10% for children and BMI <18.5 kg/m2 for adults, and overweight or obese status defined as BMIp >85% for children and BMI >25 kg/m2 for adults. Analyses were adjusted for patient sociodemographic and clinical characteristics., Results: The study population included 11,971 pediatric and 14,817 adult PwCF. A total of 137 CF programs responded to the survey, representing 71% of the pediatric sample and 45% of the CFFPR adult sample. The joint models of nutritional status as a function of both program-level food insecurity screening and area-level food access produced the following findings. Among children with CF, screening at every visit vs less frequently was associated with 39% lower odds of being underweight (OR 0.61, p = 0.019), and the effect remained the same and statistically significant after adjusting for all covariates (aOR 0.61, p = 0.047). Residence in a food desert was associated both with higher odds of being underweight (OR 1.66, p = 0.036; aOR 1.58, p = 0.008) and with lower BMIp (-4.81%, p = 0.004; adjusted -3.73%, p = 0.014). Among adults with CF, screening in writing vs verbally was associated with higher odds of being overweight (OR 1.22, p = 0.028; aOR 1.36, p = 0.002) and higher BMI (adjusted 0.43 kg/m2 , p = 0.032). Residence in a food desert was associated with higher odds of being underweight (OR 1.48, p = 0.025)., Conclusions: Food insecurity screening and local food access are independent predictors of nutritional status among PwCF. More frequent screening is associated with less underweight among children with CF, whereas screening in writing (vs verbally) is associated with higher BMI among adults. Limited food access is associated with higher odds of being underweight in both children and adults with CF, and additionally with lower BMI among children with CF. Study results highlight the need for standardized, evidence-based food insecurity screening across CF care programs and for equitable food access to optimize the nutritional outcomes of PwCF., Competing Interests: Declaration of Competing Interest Kim Reno and Cristen Clemm are employees of the Cystic Fibrosis Foundation. Georgia Brown is a person living with cystic fibrosis. All other co-authors served on the Cystic Fibrosis Foundation Food Security Committee and received a honorarium for their service., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
14. A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis.
- Author
-
Roesch EA, Bonfield TL, Lazarus HM, Reese J, Hilliard K, Hilliard J, Khan U, Heltshe S, Gluvna A, Dasenbrook E, Caplan AI, and Chmiel JF
- Subjects
- Humans, Adult, Administration, Intravenous, Spirometry, Cystic Fibrosis therapy, Cystic Fibrosis drug therapy, Mesenchymal Stem Cells, Hematopoietic Stem Cell Transplantation
- Abstract
Background: Mesenchymal stem cells are of particular interest in cystic fibrosis (CF) as a potential therapeutic. Data from pre-clinical studies suggest that allogeneic bone marrow-derived human mesenchymal stem cells (hMSCs) may provide a new therapeutic treatment for CF lung disease by attenuating pulmonary inflammation while decreasing bacterial growth and enhancing antibiotic efficacy., Methods: Fifteen adults with CF were enrolled in a phase 1 dose-escalation trial of a single intravenous infusion of hMSCs derived from bone marrow aspirates obtained from a single pre-clinically validated healthy volunteer donor. The study employed a 3+3 dose escalation design with subjects receiving a single, intravenous dose of either 1×10
6 , 3×106 , or 5×106 hMSCs/kg. Subjects were monitored inpatient for 24 hours and by outpatient visits and telephone calls for 12 months after the infusion. Safety and tolerability were evaluated by monitoring symptoms, patient reported outcome questionnaires, adverse events (AEs), physical exam findings, spirometry, and analyses of safety laboratories. Preliminary evidence for potential efficacy using inflammatory markers in the blood and sputum were also evaluated., Results: No dose-limiting toxicities, deaths or life-threatening adverse events were observed. Most AEs and serious adverse events (SAEs) were consistent with underlying CF. Vital signs, physical exam findings, spirometry and safety laboratory results showed no significant change from baseline. No trends over time were seen in serum or sputum inflammatory markers nor with clinical spirometry., Conclusion: Allogeneic hMSC intravenous infusions were safe and well-tolerated in this phase 1 study and warrant additional clinical testing as a potential therapeutic for CF lung disease., Competing Interests: Conflicts of Interest The authors have no conflicts of interest to disclose., (Copyright © 2022. Published by Elsevier B.V.)- Published
- 2023
- Full Text
- View/download PDF
15. Managing Cystic Fibrosis related diabetes via telehealth during COVID-19 pandemic.
- Author
-
Hasan S, Cecilia Lansang M, Salman Khan M, and Dasenbrook E
- Abstract
Coronavirus disease 2019 (COVID-19) was declared a pandemic on March 11, 2020. In efforts to reduce the risk of transmission, telehealth visits for routine care has significantly increased in the United States. Cystic fibrosis patients have been categorized as a highly vulnerable population to COVID-19 infection. Cystic Fibrosis centers are rapidly assessing and responding to the pandemic to ensure the safety of CF patients. At our Cleveland Clinic Cystic Fibrosis center, we transitioned outpatient clinics to a virtual care model in March 2020. Here, we report the changes that were implemented to optimize diabetes management in CF patients through telehealth during the COVID-19 crisis., (© 2021 Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
16. Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort.
- Author
-
Lehr CJ, Fink AK, Skeans M, Faro A, Fernandez G, Dasenbrook E, and Valapour M
- Subjects
- Case-Control Studies, Humans, Income, United States, Waiting Lists, Cystic Fibrosis surgery, Lung Transplantation, Methicillin-Resistant Staphylococcus aureus
- Abstract
Rationale: Referrals for lung transplant and transplant rates in the United States are lower than in Canada for patients with advanced cystic fibrosis (CF) lung disease. Further study of factors limiting access are needed to optimize referral and transplant for this population. Objectives: To determine the effect of socioeconomic position, while accounting for disease severity, on the likelihood of wait-listing for lung transplant in the United States. Methods: A case-control study of 3,110 patients (1,555 wait-listed, 1,555 never wait-listed) in the linked CF Foundation Patient Registry/Scientific Registry of Transplant Recipients was performed with 1:1 matching for age, forced expiratory volume in 1 second, and year. Logistic regression was performed with univariate and multivariate analyses accounting for eight clinical factors (sex, oxygen use, body mass index, hemoptysis, forced vital capacity, methicillin-resistant Staphylococcus aureus , multidrug-resistant Pseudomonas aeruginosa , and i.v. antibiotic days) and six socioeconomic factors (race, marital status, education, health insurance, median zip code income, and distance to transplant program). The CF Health Score and Socioeconomic Barrier Score were created based on summation of variables. Interactions between scores were calculated. Results: We found an inverse relationship between the probability of wait-listing and CF Health Score and Socioeconomic Barrier Score. As the CF Health Score decreased (less healthy), the probability of wait-listing increased by 69.3% from a score of 7 to 2. As the Socioeconomic Barrier Score decreased (fewer barriers), the probability of wait-listing increased by 31.7% from a score of ≥5 to 1). Regardless of illness severity, socioeconomic barriers presented an impediment to wait-listing. Individuals with higher Socioeconomic Barrier Scores accessed transplant about half as often as those with lower scores at the same level of medical severity. Analysis of interactions demonstrated a higher probability of wait-listing for individuals with moderate health severity and fewer social barriers compared with sicker individuals with more socioeconomic barriers. Conclusions: Accrual of socioeconomic barriers limits access to lung transplant irrespective of disease severity, a finding of substantial concern for patients with CF and for transplant providers. Future interventions can focus on this at-risk population early in the disease course.
- Published
- 2020
- Full Text
- View/download PDF
17. Keep cystic fibrosis patients out of the hospital.
- Author
-
Dasenbrook E
- Abstract
No specific data exists regarding management of patients with cystic fibrosis (CF) who are infected with COVID-19. Based on expert opinion, strategies for outpatient management include use of elexacaftor-tezacaftor-ivacaftor to reduce pulmonary exacerbations, telemedicine, adherence to prescribed regimens, prompt and aggressive treatment of CF exacerbations, and communication about COVID-19 with patients with CF. Strategies for inpatient management may vary due to special precautions to avoid the aerosolization of COVID-19 with the use of nebulized medications and other therapies., (Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
- Author
-
Lehr CJ, Skeans M, Dasenbrook E, Fink A, Fernandez G, Faro A, and Valapour M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Cystic Fibrosis physiopathology, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Proportional Hazards Models, Pulmonary Disease, Chronic Obstructive physiopathology, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Young Adult, Algorithms, Cystic Fibrosis diagnosis, Lung Transplantation standards, Patient Selection, Pulmonary Disease, Chronic Obstructive diagnosis, Tissue and Organ Procurement standards, Waiting Lists
- Abstract
Rationale: Clinical variables associated with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in the lung allocation score (LAS). Objectives: To identify variables associated with wait-list and post-transplant mortality for CF lung transplant candidates using a novel database and to analyze the impact of including new CF-specific variables in the LAS system. Methods: A deterministic matching algorithm identified patients from the Scientific Registry of Transplant Recipients and the Cystic Fibrosis Foundation Patient Registry. LAS wait-list and post-transplant survival models were recalculated using CF-specific variables. This multicenter, retrospective, population-based study of all lung transplant wait-list candidates aged 12 years or older from January 1, 2011, to December 31, 2014, included 9,043 patients on the lung transplant waiting list and 6,110 lung transplant recipients between 2011 and 2014, comprising 1,020 and 677 with CF, respectively. Measurements and Main Results: Measured outcomes were changes in LAS and lung allocation rank. For CF candidates, any Burkholderia sp. (hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.2-6.6), 29-42 days hospitalized (HR 2.8; CI 1.3-5.9), massive hemoptysis (HR 2.1; CI 1.1-3.9), and relative drop in FEV
1 ≥30% over 12 months (HR 1.7; CI 1.0-2.8) increased wait-list mortality risk; pulmonary exacerbation time 15-28 days (1.8; 1.1-2.9) increased post-transplant mortality risk. A relative drop in FEV1 ≥10% in chronic obstructive pulmonary disease (COPD) candidates was associated with increased wait-list mortality risk (HR 2.6; CI 1.2-5.4). Variability in LAS score and rank increased in patients with CF. Priority for transplant increased for COPD candidates. Access did not change for other diagnosis groups. Conclusions: Adding CF-specific variables improved discrimination among wait-listed CF candidates and benefited COPD candidates.- Published
- 2019
- Full Text
- View/download PDF
19. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
- Author
-
VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, and Flume PA
- Subjects
- Adult, Clinical Protocols standards, Feasibility Studies, Female, Forced Expiratory Volume drug effects, Humans, Male, Sample Size, Surveys and Questionnaires standards, Symptom Flare Up, Anti-Bacterial Agents therapeutic use, Cystic Fibrosis complications, Cystic Fibrosis diagnosis, Cystic Fibrosis drug therapy, Endpoint Determination methods, Endpoint Determination standards, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care standards, Randomized Controlled Trials as Topic methods, Respiratory Tract Infections drug therapy, Respiratory Tract Infections etiology
- Abstract
Background: Given the variability in pulmonary exacerbation (PEx) management within and between Cystic Fibrosis (CF) Care Centers, it is possible that some approaches may be superior to others. A challenge with comparing different PEx management approaches is lack of a community consensus with respect to treatment-response metrics. In this analysis, we assess the feasibility of using different response metrics in prospective randomized studies comparing PEx treatment protocols., Methods: Response parameters were compiled from the recent STOP (Standardized Treatment of PEx) feasibility study. Pulmonary function responses (recovery of best prior 6-month and 12-month FEV
1 % predicted and absolute and relative FEV1 % predicted improvement from treatment initiation) and sign and symptom recovery from treatment initiation (measured by the Chronic Respiratory Infection Symptom Score [CRISS]) were studied as categorical and continuous variables. The proportion of patients retreated within 30days after the end of initial treatment was studied as a categorical variable. Sample sizes required to adequately power prospective 1:1 randomized superiority and non-inferiority studies employing candidate endpoints were explored., Results: The most sensitive endpoint was mean change in CRISS from treatment initiation, followed by mean absolute FEV1 % predicted change from initiation, with the two responses only modestly correlated (R2 =.157; P<0.0001). Recovery of previous best FEV1 was a problematic endpoint due to missing data and a substantial proportion of patients beginning PEx treatment with FEV1 exceeding their previous best measures (12.1% >12-month best, 19.6% >6-month best). Although mean outcome measures deteriorated approximately 2-weeks post-treatment follow-up, the effect was non-uniform: 62.7% of patients experienced an FEV1 worsening versus 49.0% who experienced a CRISS worsening., Conclusions: Results from randomized prospective superiority and non-inferiority studies employing mean CRISS and FEV1 change from treatment initiation should prove compelling to the community. They will need to be large, but appear feasible., (Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
20. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
- Author
-
Sawicki GS, Dasenbrook E, Fink AK, and Schechter MS
- Subjects
- Adolescent, Adult, Child, Cross-Sectional Studies, Female, Humans, Logistic Models, Male, Multivariate Analysis, Mutation, Registries, United States, United States Food and Drug Administration, Young Adult, Aminophenols therapeutic use, Cystic Fibrosis drug therapy, Cystic Fibrosis genetics, Cystic Fibrosis Transmembrane Conductance Regulator therapeutic use, Quinolones therapeutic use
- Abstract
Rationale: Chronic cystic fibrosis (CF) therapies have variable rates of prescribed use, and therapies are rarely prescribed to more than 80% of eligible patients. Ivacaftor was approved in the United States in January 2012 for patients ages 6 years and older with a G551D mutation in their CF gene., Objectives: To examine the rate of uptake and patterns of documented ivacaftor use among U.S. patients with CF during the first year after approval, to compare eligible patients with and without reported use, and to describe characteristics of early adopters of ivacaftor use., Methods: A cross-sectional study of patients in the U.S. Cystic Fibrosis Foundation Patient Registry in 2012 with at least one encounter in which ivacaftor use was documented. Ivacaftor-eligible patients were defined as any individual 6 years of age or older with a G551D mutation. We performed bivariate and multivariate regression analyses, stratified by age group, to compare clinical and demographic characteristics of (1) eligible patients with and without documented ivacaftor use in 2012 and (2) early (February-June) versus late (July-December) adopters in 2012., Measurements and Main Results: A total of 1,087 patients with CF with G551D mutations were in the U.S. Cystic Fibrosis Foundation Patient Registry in 2012. By June 2012, 64% of eligible patients had documented ivacaftor use, which increased to 81% by the end of 2012. Among eligible patients younger than 18 years of age, 85% were prescribed ivacaftor, with significantly lower odds among those with higher BMI percentile, fewer clinical encounters in 2011, and later age at diagnosis. Among eligible patients age 18 years or older, 79% were prescribed ivacaftor, with significantly lower odds in nonwhite patients and those with later age at diagnosis. Documented prescriptions of ivacaftor also varied by state of residence, with a range of 42-100% of eligible patients across states. The only association with early adoption of ivacaftor in 2012 was a decreased likelihood in adults with fewer than four encounters in 2011., Conclusions: Uptake of ivacaftor use among eligible patients in the United States was rapid, with the majority of use initiated within 4 months of regulatory approval. Differences in ivacaftor prescriptions appear to be related to patient age, older age at diagnosis, and less frequent clinical encounters. Nutritional status also appears to play a role in children, and race seems to have an association in adults.
- Published
- 2015
- Full Text
- View/download PDF
21. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
- Author
-
Zobell JT, Epps KL, Young DC, Montague M, Olson J, Ampofo K, Chin MJ, Marshall BC, and Dasenbrook E
- Subjects
- Adult, Child, Cross-Sectional Studies, Drug Administration Schedule, Drug Therapy, Combination, Health Care Surveys, Humans, Linezolid therapeutic use, Rifampin therapeutic use, Staphylococcal Infections complications, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use, Vancomycin therapeutic use, Anti-Bacterial Agents therapeutic use, Cystic Fibrosis complications, Methicillin-Resistant Staphylococcus aureus, Practice Patterns, Physicians', Staphylococcal Infections drug therapy
- Abstract
Objectives: The purpose of this study was to characterize the utilization of antibiotics for chronic methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients with acute pulmonary exacerbations (PEx)., Methods: An anonymous national cross-sectional survey of CF Foundation accredited care programs was performed using an electronic survey tool., Results: Fifty-eight percent (152/261) CF Foundation accredited programs completed the survey. Ninety-eight percent (149/152) of respondents reported using antibiotics (oral or intravenous) against MRSA. Variability exists in the use of antibiotics amongst the programs and in the dosages utilized. For oral outpatient treatment, sulfamethoxazole/trimethoprim was the most commonly utilized antibiotic by both pediatric (109/287, 38%) and adult (99/295, 34%) respondents, of which, ten percent of reported to use it in combination with rifampin. For inpatient treatment, linezolid (both intravenous (IV) and oral) was most commonly utilized in both pediatric (IV 35/224, 16%; oral 41/224, 18%), and adult (IV 44/235, 19%; oral 38/235, 16%) respondents for inpatient treatment. IV vancomycin was the second most commonly utilized antibiotic by pediatric (70/224, 31%) and adult (71/235, 30%) respondents. Most respondents reported dose titration to achieve a vancomycin trough level of 15-20 mg/L (150/179, 84%). Topical or inhaled antibiotic utilization was reported to be an uncommon practice with approximately 70% of pediatric and adult respondents reporting to use them either rarely or never. The concomitant use of anti-MRSA and anti-pseudomonal antibiotics was common with 96% of pediatric and 99% of adult respondents answering in the affirmative., Conclusion: We conclude that anti-MRSA antibiotics are utilized via various dosage regimens by a majority of CF Foundation accredited care programs for the treatment of chronic MRSA in PEx, and there is no consensus on the best treatment approach., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.